PM360
DECEMBER 14, 2023
Empowering patients with comprehensive information about their health and medical conditions is a critical step towards fostering their active involvement in healthcare decisions. By equipping them with knowledge, patients can make more informed choices and collaborate effectively with healthcare providers (HCPs), ultimately enhancing the quality of care they receive.
Fierce Pharma
DECEMBER 14, 2023
Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 13, 2023
Health systems have been increasingly dropping MA contracts, saying that they cause their organizations to lose too much money and result in dangerous patient care delays. To mitigate this issue, experts think large MA plans need to delegate more utilization management duties to health systems rather than handling it themselves.
PharmaVoice
DECEMBER 15, 2023
Markups for generics can be as high as 7,000%, the researchers said.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
European Pharmaceutical Review
DECEMBER 12, 2023
Yannis Morel, Executive Vice President of product portfolio strategy and business development of Innate Pharma SA, offers insight on engineering antibodies to develop antibody-based NK cell therapeutics. He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment.
Fierce Pharma
DECEMBER 13, 2023
Using Tuesday to announce good news—that its $43 billion acquisition of Seagen would be | Using Tuesday to announce good news—that its $43 billion acquisition of Seagen would be finalized on Thursday—Pfizer sandwiched its bad news, which came on Wednesday with its 2024 guidance. The company expects revenue to reach between $58.5 billion and $61.5 billion next year, coming up short of the analyst consensus of $63.2 billion, largely because of the plummeting demand for its COVID-19 products.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
DECEMBER 15, 2023
MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory filing.
PharmaTimes
DECEMBER 14, 2023
The collaboration aims to develop biomarker-based diagnostics for the condition - News - PharmaTimes
Fierce Pharma
DECEMBER 12, 2023
Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S. | Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Inclusion in the list doesn’t mean a particular drug is likely to experience a shortage anytime soon, the EMA said.
MedCity News
DECEMBER 13, 2023
About eight in 10 employers think drug costs, high-cost claims and hospital prices are a “significant threat to affordability,” according to a new survey from National Alliance of Healthcare Purchaser Coalitions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
DECEMBER 11, 2023
Results from MaaT Pharma’s Early Access Program (EAP) for its microbiome-based therapy MaaT013, have demonstrated positive overall response and overall survival rates in European patients with graft-versus-host disease (GvHD). The findings were presented at the 2023 American Society of Hematology (ASH) Annual Meeting. MaaT013 is an off-the-shelf, pooled-donor, enema Microbiome Ecosystem Therapy TM.
PharmaTimes
DECEMBER 13, 2023
In England, ruptured brain aneurysms occur in around one in 15,000 people every year - News - PharmaTimes
Fierce Pharma
DECEMBER 15, 2023
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK. | About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
MedCity News
DECEMBER 14, 2023
There are a lack of women at venture capital firms. This makes it difficult for women’s health startups focused on stigmatized conditions to get funding when pitching to those who don’t always have a good understanding, startups say.
pharmaphorum
DECEMBER 15, 2023
MSD claims 2nd FDA approval for Welireg, in kidney cancer Phil.
PharmaTimes
DECEMBER 11, 2023
New data highlights the inequalities in emergency hospital rates and vaccinations - News - PharmaTimes
Fierce Pharma
DECEMBER 14, 2023
Despite the high list price of Lyfgenia, bluebird has signed a large reimbursement deal for the sickle cell disease (SCD) gene therapy less than a week after its
MedCity News
DECEMBER 13, 2023
Google introduced a new suite of healthcare-focused generative AI models designed to speed up workflows for clinicians and medical researchers. Health systems and medical research organizations, including HCA Healthcare and BenchSci, have been testing these models since April.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
DECEMBER 14, 2023
In the ever-evolving landscape of regulatory decisions, the quest for safeguarding public health remains paramount. Decisions to remove medicines from market are not taken lightly and are often based upon all evidence available to inform a benefit/risk balance. This evidence can come from a range of sources, such as randomised controlled trials (RCTs), observational studies, and spontaneous reporting.
pharmaphorum
DECEMBER 13, 2023
Pharnext hit again as rare disease drug flunks phase 3 test Phil.
Fierce Pharma
DECEMBER 12, 2023
To complete its acquisition of Seagen, what did Pfizer need to do to satisfy antitrust concerns of the Federal Trade Commission? | By agreeing to donate royalties on its U.S. sales of bladder cancer drug Bavencio, Pfizer has received the go-ahead to finalize its $43 billion buyout of Seagen, the company said on Tuesday. Pfizer expects to close the merger on Thursday.
MedCity News
DECEMBER 12, 2023
The Lower Costs, More Transparency Act has passed in the House with bipartisan support. The action is being applauded from several advocacy organizations.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
DECEMBER 15, 2023
Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. The randomised study, KEYNOTE-942, evaluated the treatment in patients with high-risk stage III/IV melanoma. Analysis shows that after three years, treatment with mRNA-4157 (V940) in combination with checkpoint inhibitor Keytruda reduced the risk of recurrence or death by 49 percent compared w
PharmExec
DECEMBER 13, 2023
Lisa Conte, founder, president, and CEO of Jaguar Health, discusses how a climb up Mount Kilimanjaro would vault her to her true career calling—and spark a decades-long quest to accelerate breakthroughs in plant-based pharmaceuticals and supportive care.
Fierce Pharma
DECEMBER 15, 2023
Since Merck secured approval for kidney cancer pill and blockbuster hopeful Welireg (belzutifan) in August of 2021, sales have grown slowly but surely. | Since Merck secured approval for kidney cancer pill and blockbuster hopeful Welireg (belzutifan) in August of 2021, sales have grown slowly but surely. With a second FDA nod for a much larger patient population, the company can anticipate a more pronounced upswing in revenue from the hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor.
MedCity News
DECEMBER 11, 2023
Fruit Street Health’s complaint alleged that Sharecare violated the terms of their shared business agreement by rolling out its own version of Fruit Street’s diabetes prevention program, which had been previously offered to Sharecare members. Sharecare said that the lawsuit is baseless.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
DECEMBER 11, 2023
MSD, Moderna take mRNA jab into phase 3 for lung cancer Phil.
PharmaTimes
DECEMBER 11, 2023
Around 2,100 GP surgeries had enrolled into the digital service by the end of November - News - PharmaTimes
Fierce Pharma
DECEMBER 12, 2023
Genentech’s brief leadership interregnum is coming to an end as the company’s interim chief executive, Ashley Magargee, prepares to take a permanent place on the throne. | Genentech veteran Ashley Magargee, who was tapped to temporarily steer the Roche subsidiary in November, will don the mantle of full-time CEO on Jan. 1, 2024. The executive move comes amid a period of C-suite fluidity for Roche and its large pharma group.
MedCity News
DECEMBER 10, 2023
Deloitte released a report predicting the key trends that will shape the healthcare landscape in 2024. Some of them include hospital M&A, health systems outsourcing departments and the increasing adoption of generative AI tools.
Expert insights. Personalized for you.
98 
Let's personalize your content